With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

DNA

Michael Gilman didn't have much time to enjoy "retirement" after Bristol-Myers Squibb Co. acquired his last company Padlock Therapeutics Inc. for up to $600m. Within months he was immersed in multiple new opportunities, the first of which, Arrakis Therapeutics, has closed a $38m Series A venture capital round.

The Bristol-Myers acquisition of Padlock was announced in March and by April, during his last week at BMS, Gilman heard about Arrakis and its RNA-targeting small molecule platform from his former Biogen colleague Russell Petter. (Also see "Value Unlocked: BMS Buying Padlock For Up To $600m " - Scrip, 24 March, 2016.) Biogen is the company that acquired Stromedix Inc., another Gilman-run biopharma firm, in 2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.